心脏骤停存活者接受目标温度管理后血脑屏障破坏程度与神经预后的关联
这项回顾性单中心研究纳入2018年4月至2019年12月接受TTM的68例OHCA存活者,于自主循环恢复后即刻及24、48、72小时计算白蛋白商(QA),并按QA值分级赋分评估血脑屏障破坏程度。6个月时37例(54%)神经预后不良;中重度血脑屏障破坏者中各时点不良预后比例均高于轻/正常者(第1天80% vs 50%,第2天79% vs 32%,第3天81% vs 30%,第4天85% vs 30%,P<0.001)。ROC分析显示QA及评分系统对不良预后有预测价值,评分>9时敏感度91.9%、特异度87.1%。作者认为QA与不良神经预后相关,但需大型多中心前瞻性研究验证其预测效用。
要点
- 中重度血脑屏障破坏者6个月不良神经预后比例:第1天19/22(80%)vs 18/46(50%),第2天31/37(79%)vs 6/31(32%),第3天32/37(81%)vs 5/31(30%),第4天32/39(85%)vs 5/29(30%),P<0.001。
- QA预测不良预后的最佳截断值:第1天>0.009(敏感度56.8%,特异度87.1%),第2天>0.012(81.1%,87.1%),第3天>0.013(83.8%,87.1%),第4天>0.013(86.5%,87.1%)。
- 各时点QA之和>0.039预测不良预后敏感度89.5%、特异度79.4%;血脑屏障破坏评分>9时敏感度91.9%、特异度87.1%。
- 血脑屏障破坏评分:QA≤0.007为正常(0分),>0.007-0.01为轻度(1分),>0.01-0.02为中度(4分),>0.02为重度(9分)。
- 作者认为QA与OHCA接受TTM者不良神经预后相关,但需大型多中心前瞻性研究验证其预测效用。
适用人群与场景
- 2018年4月至2019年12月期间接受目标温度管理(TTM)及腰大池引流的院外心脏骤停(OHCA)存活者68例(男48例,71%)。
- 无腰大池引流禁忌证者。
诊断标准与关键阈值
- 血脑屏障破坏程度按白蛋白商(QA=脑脊液白蛋白/血清白蛋白)分级:QA≤0.007为正常(0分),QA>0.007-0.01为轻度(1分),QA>0.01-0.02为中度(4分),QA>0.02为重度(9分)。
- 神经预后于自主循环恢复后6个月采用脑功能分类(CPC)评定,CPC 1-2分为预后良好,CPC 3-5分为预后不良。
研究设计与关键结果
- 回顾性单中心研究纳入68例OHCA接受TTM及腰大池引流的存活者,37例(54%)6个月神经预后不良。
- 中重度血脑屏障破坏者6个月不良预后比例:第1天19/22(80%)vs 18/46(50%),第2天31/37(79%)vs 6/31(32%),第3天32/37(81%)vs 5/31(30%),第4天32/39(85%)vs 5/29(30%),P<0.001。
- ROC分析QA预测不良预后的最佳截断值(敏感度,特异度):第1天>0.009(56.8%,87.1%),第2天>0.012(81.1%,87.1%),第3天>0.013(83.8%,87.1%),第4天>0.013(86.5%,87.1%),各时点QA之和>0.039(89.5%,79.4%),评分系统>9(91.9%,87.1%)。
证据类型、等级与局限
- 证据类型:回顾性单中心研究(概念验证研究)。
- 局限:原文作者指出需大型多中心前瞻性研究验证血脑屏障破坏作为神经预后预测指标的效用。
对床旁实践的改变
- 作者认为,在无腰大池引流禁忌证的OHCA接受TTM存活者中,QA与不良神经预后相关,血脑屏障破坏评分可能作为预后预测指标,但需大型多中心前瞻性研究验证。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: This study aimed to compare day-specific associations of blood-brain barrier (BBB) disruption with neurological outcome in survivors of out-of-hospital cardiac arrest (OHCA) treated with target temperature management (TTM) and lumbar drainage.
METHODS: This retrospective single-center study included 68 survivors of OHCA who underwent TTM between April 2018 and December 2019. The albumin quotient (QA) was calculated as QA = albumincerebrospinal fluid/albuminserum immediately (day 1) and 24 (day 2), 48 (day 3), and 72 h (day 4) after the return of spontaneous circulation. The degree of BBB disruption was weighted using the following scoring system: QA value of 0.007 or less (normal), QA value greater than 0.007-0.01 (mild), QA value greater than 0.01-0.02 (moderate), and QA value greater than 0.02 (severe). Points were assigned as follows: 0 (normal), 1 (mild), 4 (moderate), and 9 (severe). Neurological outcome was determined at 6 months after the return of spontaneous circulation, as well as cerebral performance category (CPC), dichotomized as good (CPC score 1-2) and poor (CPC score 3-5) outcome.
RESULTS: We enrolled 68 patients (48 men, 71%); 37 (54%) patients had a poor neurological outcome. The distributions of poor versus good outcomes at 6 months in patients with moderate and severe BBB disruption were 19 of 22 (80%) vs. 18 of 46 (50%) on day 1, 31 of 37 (79%) vs. 6 of 31 (32%) on day 2, 32 of 37 (81%) vs. 5 of 31 (30%) on day 3, and 32 of 39 (85%) vs. 5 of 29 (30%) on day 4 (P < 0.001), respectively. Using receiver operating characteristic analyses, optimal cutoff values (sensitivity, specificity) of QA levels for the prediction of neurological outcome were as follows: day 1, greater than 0.009 (56.8%, 87.1%); day 2, greater than 0.012 (81.1%, 87.1%); day 3, greater than 0.013 (83.8%, 87.1%); day 4, greater than 0.013 (86.5%, 87.1%); the sum of all time points, greater than 0.039 (89.5%, 79.4%); and scoring system, greater than 9 (91.9%, 87.1%).
CONCLUSIONS: In this proof of concept study, QA was associated with poor neurological outcome in survivors of OHCA treated with TTM with no contraindication to lumbar drainage. A large multicenter prospective study is needed to validate the utility of BBB disruption as a prognosticator of neurological outcome.
参考来源
- Jeon GR, Ahn HJ, Park JS, et al. The Association Between Neurological Prognosis and the Degree of Blood-Brain Barrier Disruption in Cardiac Arrest Survivors Who Underwent Target Temperature Management. Neurocrit Care. 2021. PMID: 34136993. doi:10.1007/s12028-021-01241-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。